A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Trial Profile

A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ImmusanT
  • Most Recent Events

    • 31 Oct 2017 According to an ImmusanT media release, data were presented at the United European Gastrointestinal (UEG) Week, Nov 2017.
    • 12 Oct 2017 According to an ImmusanT media release, data from this trial will be presented at the United European Gastrointestinal (UEG) Week, Nov 2017.
    • 12 May 2017 Results from this and other trial (see profile 215705) published in an ImmusanT Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top